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INTRODUCTION
Radical nephroureterectomy with bladder cuff resection
is the standard treatment for patients with transitional cell
carcinoma of the upper urinary tract (UUT-TCC). Even after
this radical procedure (1, 2), however, UUT-TCC shows high
rates of local recurrence and systemic disease, with lymph
nodes as the major site of metastases (3-5).
In bladder cancer, extended lymphadenectomy improves
both staging and prognosis (6-8). The role of lymphadenec-
tomy in the surgical treatment of UUT-TCC is more diffi-
cult to establish, because the disease is relatively rare. Sever-
al recent studies have suggested a possibly curative effect of
lymph node dissection in the treatment of patients with infil-
trative UUT-TCC (9-13). 
Nonetheless, lymphadenectomy is not used routinely, for
either therapy or staging, especially in clinically N0 UUT-
TCC. In this study, we investigated the clinical significance
of lymph node dissection (LND) in patients with cN0 mus-
cle-invasive UUT-TCC who underwent nephroureterecto-
my.
MATERIALS AND METHODS
Study population 
We reviewed the medical records of patients with muscle-
invasive UUT-TCC who underwent open nephroureterecto-
my in a single institution between January 1986 and Decem-
ber 2005. Patients with distant metastasis at diagnosis, unre-
sectable lesions, and concomitant invasive bladder cancer were
excluded. Patients in whom lymph node involvement was
suspected on preoperative imaging studies or operative find-
ings were also excluded. A total of 152 patients were eligible
for this study, including 103 male patients (67.8%), and 49
female patients (32.2%). The median age was 65 yr (range,
25 to 86 yr), and the median follow-up duration was 53 mon-
ths (range, 6 to 214 months) (Table 1). 
Treatments and follow-ups
All patients had undergone nephroureterectomy with blad-
der cuff excision. Regional LND and its extent were deter-
mined at the surgeon’s discretion, because the role of LND is
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not yet established, especially in UUT-TCC patients without
evidence of lymph node involvement. The indication for adju-
vant chemotherapy was disease infiltrating the surrounding
adipose tissue, or histological confirmation of lymph node in-
volvement. The final decision on chemotherapy, however, was
based on a combination of factors, including coexisting con-
ditions, and the patient’s ability and willingness to comply.
Patient follow-up was relatively uniform and included surveil-
lance cystoscopy, urinary cytology, abdomen-pelvis computed
tomography (CT), whole body bone scan, and chest radiog-
raphy, performed at 3-month intervals for the first 2 yr, at 6-
month intervals for the subsequent 3 yr, and annually thereafter.
Study methods
Clinical information was obtained by a retrospective review
of all relevant medical records. Locoregional recurrence (LR)
was defined as ipsilateral pelvic lymph node enlargement,
or iliac fossa tumor recurrence in lower ureteral tumors, and
para-aortic, paracaval, aortocaval, renal hilar lymph node en-
largement, or renal fossa tumor recurrence in renal pelvic or
upper 2/3 ureteral tumors. A lymph node of 1 cm or more,
based on an abdomen-pelvis CT scan, was considered a metas-
tasized node. Disease recurrence (DR) was defined as distant
metastasis and/or LR. The T-stage and tumor grade of each
tumor were determined according to the 2002 American Joint
Committee on Cancer (AJCC) TNM staging system and the
1998 World Health Organization/International Society of
Urologic Pathologists (WHO/ISUP) classification of papil-
lary urothelial neoplasia (14, 15). 
We investigated the difference in LR and DR according
to the number of lymph nodes harvested, using the chi-square
test and linear-by-linear association. To evaluate the impact
of various clinical and pathological features on LR, DR, and
disease-specific survival, we used the Kaplan-Meier methods
and log-rank test. The multivariate Cox proportional hazards
model was used for multivariate survival analyses. Calcula-
tions were performed with the Statistical Package for Social
Sciences (SPSS) for Windows, version 12.0, and a two-tailed
P value of less than 0.05 was considered to be significant.
RESULTS
Sixty-three patients (41.4%) underwent LND, with a medi-
Number (%) of patients Parameters
Sex
Female 49 (32.2)
Male 103 (97.8)
Age
<65 yr 76 (50.0)
> 65 yr 76 (50.0)
Location
Ureter 72 (47.4)
Renal pelvis 80 (52.6)
Tumor size
<3 cm 66 (43.4)
≥3 cm 86 (56.6)
Multiplicity
Single 119 (78.3)
Multiple 33 (21.7)
T-stage
T2 47 (30.9)
T3 98 (64.5)
T4 7 (4.6)
Tumor grade
Low grade 14 (9.2)
High grade 138 (90.8)
No. of lymph nodes harvested
0 89 (58.6)
1 to 5 30 (19.7)
≥6 33 (21.7)
N stage
pN0 54 (35.5)
pNx 89 (58.6)
pN+ 9 (5.9)
Adjuvant chemotherapy
Not performed 105 (69.1)
Performed 47 (30.9)
Total 152 (100.0)
Table 1. Subject characteristics
NLN, number of lymph nodes harvested.
Locoregional recurrence
Number of patients with recurrence/Number of patients
NLN=0
T stage
0<NLN<6 NLN≥6 Total
Disease recurrence
NLN=0 0<NLN<6 NLN≥6 Total
T2 10/34 0/7 0/6 10/47 14/34 0/7 4/6 18/47
2
trend=4.095, P trend=0.043 2trend=0.093, P trend=0.760
T3, 4 14/55 2/23 3/27 19/105 21/55 10/23 14/27 45/105
2
trend=3.157, P trend=0.076 2trend=1.357, P trend=0.244
Total 24/89 2/30 3/33 29/152 35/89 10/30 18/33 63/152
2
trend=6.755, P trend=0.009 2trend=1.558, P trend=0.212
Table 2. Comparisons of locoregional recurrence and disease recurrence according to T stage and number of lymph nodes harvested
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an number of 6 lymph nodes harvested (range, 1 to 35). Of
these 63 patients, 9 patients showed lymph node involvement
(14.3%) (Table 1). During follow-up, LR occurred in 29 pa-
tients (19.1%), DR in 63 patients (41.4%), and disease-spe-
cific death in 55 patients (36.2%). Five-year LR-, DR-free,
and disease-specific survival rates were 78.2%, 56.9%, and
66.1%, respectively.
A chi-square test of linear trend showed that when patients
were subdivided into three groups, based on median number
of lymph nodes harvested (n=0, 0<n<6, n≥6), an increase
in the number of lymph nodes harvested was associated with
the reduction of LR ( 2trend=6.755, P=0.009), especially in
the T2 subgroup ( 2trend=4.095, P=0.043). The T3, T4 sub-
groups showed a linear trend with borderline significance
( 2trend=3.157, P=0.076). However, the number of lymph
nodes harvested and DR ( 2trend=1.558, P=0.212) were not
related (Table 2). 
In the survival analysis, T stage had a significant influence
on LR-free (P=0.0002), DR-free survival (P=0.0002), and
disease-specific survival (P=0.0009), but tumor location, size,
multiplicity, grade, and adjuvant chemotherapy did not affect
LR-free, DR-free, or disease-specific survival (P>0.05) (Table
3). The N stage (P=0.0251) and LND (P=0.0073) had a sig-
nificant influence on LR-free survival, but not on DR-free
and disease-specific survival (P>0.05) (Table 3). Multivari-
ate Cox proportional hazards models revealed that N stage
(P=0.041) and LND (P=0.012) were independently related
to LR-free survival (Table 4). Although patients who did not
undergo LND had a higher probability of LR than those who
did, there was no difference in LR-free, DR-free, and disease-
specific survival curves according to the number of lymph
nodes harvested (0<n<6 vs. n≥6) (Fig. 1). Patients with pNx
tumors showed a poorer LR-free survival curve than those
with pN0 tumors (P=0.0074, Fig. 1); however, there was no
difference between these two tumor types in the DR-free or
disease-specific survival curves (P>0.05).
DISCUSSION
Regional lymphadenectomy is widely accepted in the man-
agement of bladder cancer, because extended lymphadenec-
tomy improves staging and prognosis (6-8). In UUT-TCC,
the role of LND is less clear. Although UUT-TCC is histo-
logically similar to bladder cancer, and LND improves stag-
ing, data do not yet support a therapeutic benefit from thisRFS, recurrence-free survival rate; DSS, disease-specific survival rate.
5 yr 
RFS (%)
P
value
Locoregional
recurrence
5 yr 
DSS (%)
P
value
Disease-specific
death
5 yr 
RFS (%)
P
value
Disease 
recurrence
Location 0.7089 0.9403 0.7828
Renal pelvis 81.0 58.9 67.1
Ureter 75.1 54.8 65.0
Tumor size 0.7472 0.1515 0.0526
<3 cm 74.2 60.9 69.3
≥3 cm 81.6 53.9 61.4
Multiplicity 0.2385 0.5932 0.2846
Single 75.8 53.3 62.8
Multiple 86.3 63.6 72.0
T-stage 0.0002 0.0002 0.0009
T2 82.2 62.7 68.6
T3 77.2 54.1 63.8
T4 26.7 14.3 28.5
Tumor grade 0.2099 0.2826 0.3420
Low grade 91.6 67.7 65.9
High grade 76.8 56.0 64.4
N stage 0.0251 0.1318 0.4598
pN0 90.9 59.5 72.3
pN+ 80.0 29.6 66.7
pNx 70.6 58.2 62.7
Lymph node 0.0073 0.6665 0.9473
dissection
Not performed 70.6 58.2 62.7
Performed 89.9 55.0 71.0
Adjuvant chemo- 0.1234 0.1074 0.0650
therapy
Not performed 75.0 53.0 60.4
Performed 85.8 68.3 82.6
Table 3. Survival analysis of locoregional recurrence, disease
recurrence, and disease-specific death
HR, hazard ratio; CI, confidence interval.
Model (A)
HR 95% CI P value
Model (B)
HR 95% CI P value
T stage 0.001 0.002
T3 vs. T2 0.909 0.402-2.054 0.818 0.936 0.418-2.096 0.872
T4 vs. T2 6.850 2.106-22.280 0.001 6.774 2.084-22.013 0.001
N stage 0.041 -
N+ vs. N0 2.446 0.266-22.470 0.429 - - -
Nx vs. N0 3.912 1.351-11.327 0.012 - - -
Lymph node dissection
Not performed vs. performed - - - 3.460 1.312-9.127 0.012
Table 4. Multivariate Cox proportional hazards model for locoregional recurrence
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procedure, and the variability in the lymphatic drainage pre-
cludes a standard template for LND. Urologists tend to omit
lymphadenectomy at the time of nephroureterectomy if no
evidence is found for lymph node involvement by surgical
or radiological evaluation. Our study shows, however, that
approximately 15% of patients with cN0 muscle-invasive
UUT-TCC experience LR. 
Komatsu et al. first suggested a therapeutic benefit for lym-
phadenectomy based on two long-term survivors with lymph
node metastases, one of whom received adjuvant chemother-
apy and one who did not (10). Park et al. reported a more
favorable outcome for patients with UUT-TCC treated with
lymphadenectomy, as compared with previous studies, and
suggested that this surgical procedure had specifically in-
creased survival (16). However, the therapeutic effect of rou-
tine lymphadenectomy for patients with UUT-TCC has not
been specifically evaluated. 
Although not yet confirmed prospectively, two recent ret-
rospective studies support the therapeutic use of lymphade-
nectomy, in conjunction with nephroureterectomy, for UUT-
TCC. Brausi et al. maintained that retroperitoneal LND (with
five or more lymph nodes removed) and T-stage independently
influence prognosis. A Japanese study showed that patients
who underwent complete lymphadenectomy (with a median
of seven lymph nodes removed) had a better prognosis than
those who did not, especially among patients with advanced
disease (≥pT3) (11). However, our study demonstrated that
an increased number of lymph nodes harvested was associat-
ed with the reduction of LR, and that LND had a significant
influence on LR-free survival, but not on DR-free and dis-
ease-specific survival. This is because distant metastasis usu-
ally coincides with locoregional spread in UUT-TCC. Miyake
et al. showed that lymphadenectomy improves prognosis in
patients with no lymph vessel invasion, but not in those with
lymph vessel invasion (12). They concluded that patients
with lymph vessel invasion have systemic disease, and that
these patients should receive aggressive systemic adjuvant
therapies rather than regional lymphadenectomy. These obser-
vations are consistent, in part, with ours.
Kondo et al. showed that the primary site of lymph node
metastasis depends on the primary tumor location and lateral
orientation (17). Although this study does not provide a well-
defined template for LND that may be generally applied, it
does take a significant step toward determining the optimal
extent of lymphadenectomy. They recommend that radical
lymphadenectomy for right renal pelvic and ureteral tumors
should extend to the posterior aspect of the inferior vena cava
by transection of the lumbar veins. When the tumors are locat-
ed at the upper and middle ureter, the dissection should extend
further, to the inter-aortocaval nodes. In contrast, lympha-
denectomy for tumors of the left renal pelvis and upper two-
thirds of the left ureter should extend only to the renal hilum
and para-aortic nodes. Clearly, either a hilar or a limited LND
will not remove all of the primary lymphatic drainage area
of the kidneys or ureters.
It is well known that lymph node involvement is closely
associated with T stage and tumor grade (10, 13, 17). Kondo
and his colleagues reported that the incidence of lymphatic
involvement varied according to stage and grade, with 0%,
5%, 24%, and 84% of Tis-1, T2, T3, and T4 tumors, and
0%, 11%, and 35% of G1, G2, and G3 tumors, respective-
ly, showing such involvement (17). Regional lymphadenec-
tomy might be safely omitted in UUT-TCC patients with
low-grade or low-stage tumors at preoperative biopsy or imag-
ing evaluation. However, CT or magnetic resonance imag-
ing prior to surgery may not clearly reveal T1 and T2 disease,
and sampling error, particularly with larger tumors, may limit
the accuracy in grading. Relevant to this are recent studies
showing that laparoscopic procedures for radical nephroute-
rectomy may facilitate patient recovery, with disease control
Fig. 1. Locoregional recurrence-free survival curves according to number of lymph nodes harvested (A) and N stage (B).
NLN, number of lymph nodes harvested.
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comparable to that of traditional open surgery. But although
oncological outcomes for the two procedures compare favor-
ably, questions remain concerning lymphadenectomy, espe-
cially if radical in extent, because laparoscopic retroperitoneal
LND in conjunction with nephroureterectomy presents a tech-
nical challenge (18-20). Typically, the use, extent, and pat-
tern of LND in UUT-TCC have been left to the surgeon’s
discretion, and for this reason, a large number of patients with
UUT-TCC has rarely, if ever, received lymphadenectomy in
the same clinical setting (13). From this point of view, prospec-
tive randomized studies are needed to define the indications,
most effective techniques, and optimal anatomical range for
lymphadenectomy.
In conclusion, we found that approximately 15% of patients
with cN0 muscle-invasive UUT-TCC who received LND
showed lymph node involvement on pathologic examination.
Our results suggest that LND can improve the control of
locoregional cancer, as well as staging accuracy, but that LND
does not clearly influence survival in patients with this dis-
ease.
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